BMC
LYEL icon

Bear Mountain Capital’s Lyell Immunopharma LYEL Stock Holding History

Bear Mountain Capital’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-305
Closed -$12.9K – 230
2023
Q4 		$12.9K Buy
+305
New +$11K 0.01% 111

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bear Mountain Capital's LYEL Position: Q1 2024 in Review

Bear Mountain Capital sold out of Lyell Immunopharma (LYEL) in Q1 2024, closing a stake of 305 shares — an estimated $12.9K sold.

Bear Mountain Capital first reported a position in LYEL in Q4 2023 and held it in 1 quarter. The position peaked at $12.9K in Q4 2023. 127 funds tracked by Wall St. Rank hold LYEL as of Q1 2024.

  • Bear Mountain Capital reported no remaining Lyell Immunopharma position as of Q1 2024 after selling out during the quarter.
  • Bear Mountain Capital sold 305 Lyell Immunopharma shares in Q1 2024, an estimated $12.9K.
  • Bear Mountain Capital first reported a position in Lyell Immunopharma in Q4 2023 and held it in 1 quarter.
  • Bear Mountain Capital's Lyell Immunopharma position peaked at $12.9K in Q4 2023.
  • 127 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2024.

Based on Bear Mountain Capital's 13F filing for Q1 2024, filed 25 Apr 2024.